The global Cell and Gene Therapy Clinical Trial Market is witnessing remarkable growth, with sales valued at US$ 10.7 billion in 2021. The market is projected to expand at an impressive CAGR of 24.9% from 2022 to 2032, reaching a valuation of US$ 119.3 billion by 2032.
Oncology, the highest revenue-generating segment, is forecasted to grow at a CAGR of 27.9% during the same period, driven by the increasing prevalence of cancer and the ongoing innovation in cell and gene therapies targeting oncological conditions.
Market Drivers:
- Innovations in Therapeutics: Advancements in cell and gene therapy research are transforming treatments for chronic diseases, particularly in oncology.
- Rising Investment: Substantial investments by pharmaceutical companies and research institutions to accelerate clinical trials and commercialization of novel therapies.
- Regulatory Support: Favorable policies and expedited approval pathways by regulatory agencies to bring innovative therapies to market faster.
- Global Prevalence of Chronic Diseases: A surge in chronic and genetic disorders necessitating advanced therapeutic solutions.
Key Highlights:
- The market is expected to grow nearly 11-fold between 2022 and 2032, reflecting its transformative potential in healthcare.
- Oncology remains the leading segment, driven by its critical role in advancing cancer treatment options.
- Rapid technological advancements and collaborations between biotech firms and academic institutions are fueling the expansion of the market.
Grab Your Complete Report Instantly – https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-clinical-trial-market
Key Takeaway:
The Cell and Gene Therapy Clinical Trial Market is on a trajectory of unprecedented growth, underscoring the paradigm shift towards personalized and regenerative medicine. With oncology leading the charge, the sector promises to reshape global healthcare delivery by 2032.
Market Drivers
- Increasing R&D Investments: There is a substantial rise in research and development funding for cell and gene therapies, which is driving innovation and clinical trials in this field.
- Growing Demand for Innovative Therapies: The need for novel treatment options for complex diseases, particularly cancers and genetic disorders, is fueling market growth.
- Regulatory Support: Favorable regulatory environments are encouraging the development and approval of cell and gene therapies, facilitating faster entry into the market.
- Technological Advancements: Innovations in gene editing technologies, such as CRISPR, and improved delivery methods are enhancing the efficacy of therapies.
- Increased Prevalence of Chronic Diseases: The rising incidence of chronic conditions that require advanced therapeutic interventions is propelling demand for clinical trials in this sector.
Regional Insights
- The North American region is expected to dominate the market due to its robust healthcare infrastructure and significant investments in biotechnology and pharmaceuticals.
- Asia-Pacific is anticipated to witness rapid growth, driven by increasing healthcare expenditures and a growing number of clinical trials.
Key Companies Profiled
- IQVIA Holdings Inc.
- Medpace Holdings Inc.
- Gilead Sciences
- Dendreon
- Vericel
- Novartis
- Amgen
Competitive Analysis
Some of the key players in the cell and gene therapy market include IQVIA Holdings Inc., Medpace Holdings Inc., Gilead Sciences, Dendreon, Vericel, Novartis, and Amgen.
Some of the recent developments of key Cell and Gene Therapy Clinical Trial providers are as follows:
- In March 2020, Rexenbio and Ultragenyx Pharmaceutical collaborated on the use of the NAV technology platform.
- In January 2020, Hema Care Corporation, a major operator in the manufacture of human-derived cellular products for the cell therapy market, was acquired by Charles River Laboratory for US$ 380 million.
Similarly, recent developments related to companies’ Cell and Gene Therapy Clinical Trial services have been tracked by the team at Future Market Insights, which are available in the full report.
Market Segments Covered in Cell and Gene Therapy Clinical Trial Market Analysis
By Phase:
- Phase I
- Phase II
- Phase III
By Indication:
- Oncology
- Cardiology
- CNS
- Musculoskeletal
- Infectious diseases
- Dermatology
- Endocrine
- Metabolic
- Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Other Indications
By Region:
- North America
- Latin America
- Europe
- Asia-Pacific
- Middle East & Africa (MEA)
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Vulvovaginal Candidiasis Treatment Market
Endocrine Testing Market
Near-Patient Molecular Solutions Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube